Teva Pharmaceutical Industries
在场
是其中之一......
Teva Pharmaceutical Industries 是一家在股票代码 TEVA (IL) 下上市的公司。
Teva Pharmaceutical Industries 在 21 个国家有直接业务。Teva Pharmaceutical Industries 拥有 23家子公司，其中包括 Medis Germany、Pliva 和 Teva ANZ。
高管
查看带有其 114 名主要高管的组织结构图
Teva Pharmaceutical Industries 搜索最多的简介
- Richard Francis, Director, President and Chief Executive Officer
- Perry Nisen, Director
- Tal Zaks, Director
高管在Teva Pharmaceutical Industries变化
- Christine FoxChristine Fox 将于202311月17作为 Head of US Commercial Business 加入公司 (新闻发布的2023九月29号).
- Sven Dethlefs, Executive Vice President, North America Commercial, 将于 202311月17 退休 (新闻发布的2023九月29号).
- Angus GrantAngus Grant 将于20238月1作为 Executive Vice President, Business Development 加入公司 (新闻发布的2023七月27号).
创建提醒
跟踪 Teva Pharmaceutical Industries 的高管变动
药店
Teva Pharmaceutical Industries 拥有 1,865 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- AstraZeneca has announced the acquisition of Fusion Pharma (公布2024三月23号).
- AstraZeneca has announced the acquisition of Amolyt Pharma (公布2024三月19号).
- Frontier Medicines 刚刚宣布为 80 筹款数百万美元。 (公布2024二月27号).
药店 行业的其他推荐联系人
消息
Teva Pharmaceutical Industries 的最新新闻稿
- Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
- Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
- Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
- Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
- Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
- Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
- Teva Reports Growth in Fourth Quarter and Full Year 2023
- Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
- Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- View more press releases Close
通过电子邮件
